Diamine derivatives as inhibitors of leukotriene A4 hydrolase

US7737145B2 · kind B2 · utility

Assignee

• Estrellita Pharmaceuticals, LLC · US

Inventors

• Damian O. Arnaiz · Hercules, US
• Greg Brown · Oakland, US
• Emmanuel Claret · Besançon, FR
• Arwed Cleve · Berlin, DE
• David D. Davey · El Sobrante, US
• William Guilford · San Leandro, US
• Seock-Kyu Khim · Hercules, US
• Thomas Kirkland · Atascadero, US
• Monica J. Kochanny · San Rafael, US
• Amy Liang · Richmond, US
• David Light · Branford, US
• John Parkinson · Martinez, US
• David Vogel · Richmond, US
• Guo Ping Wei · Richmond, US
• Bin Ye · Moraga, US

Key dates

• Filing date: Dec 22, 2006
• Grant date: Jun 15, 2010
• Expiry date: Aug 14, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention is directed to compounds of formula (I):where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.